Leap Bio has developed two potential "first-in-class" protein degradation agents.

Screenshot Source: ACS Publications.com Regency Bio is an emerging biopharmaceutical company dedicated to developing the world's first targeted protein degradation drug for the treatment of cancer and other serious diseases that lack effective therapies.
co-founder and chief scientific officer of the company is Dr. Xiong Yue.
study, published in JMC, researchers designed, synthesized and evaluated a range of TRK degradations.
study found that potential "first-in-class" compounds 5 and 6 induce TRK degradation, have a strong affinity for TRKs, and are expected to be highly effective TRK degraders.
study, they also found that two compounds inhibited the growth of KM12 cells, human colorectal cancer cells that express the TPM3-TRKA fusion protein, and were bioavailable in mice.
The highly selective TRK targeted protein degradation agents 5 and 6 have significantly improved drug resistance and reduced side effects from off-target toxicity, according to the Regency BioSurgery press release, which is a completely new treatment.
TRK is known as the neurotrophic factor-subject tyrosine kinase, and the fusion protein produced by the TRK mutation has been found to be found in a wide range of human malignancies, including lung cancer, colorectal cancer and soft tissue sarcoma.
addition, TRK fusion protein mutations are the main tumor drivers for rare cancers such as infant fibroblastoma, secretive breast cancer, and breast-like secretion cancer (MASC).
, TRK is considered a broad-spectrum target for cancer treatment, and the development of TRK kinase inhibitors has received attention in the pharmaceutical field.
, however, the article points out that TRK inhibitors currently approved for sale have varying degrees of drug resistance and adverse reactions (e.g. dizziness, co-effect disorders, etc.).
this, Reece Bio researchers have developed a new drug based on the principle of PROTAC, a targeted protein degrader, intended to address side effects and drug resistance in patients taking TRK inhibitors.
uSMITE, a technology platform based on protein degradation science, is based on the technology platform uSMITE, according to the ™.
drugs are usually used to interact with and reduce the activity of the functional site of the target protein, while the uSMITE™ of the re-organisms, in addition to inhibiting effects, can also use the ubigan protease system to extend the drug design to other functions, so that the target elimination of "non-drugable" enzymes and other proteins possible.
: Cullgen researchers have developed a broad-spectrum cancer target protein TRK degradation candidate drug. Retrieved Oct 20, 2020, from Source: Medical Mission Hills.